Variable | No. (%) | Median OS (months) | P | Median PFS (months) | P |
---|---|---|---|---|---|
Age (years) |  |  |  < 0.001 |  | 0.007 |
 ≥ 60 | 152 (52.96) | 11.28 |  | 5.82 |  |
 < 60 | 135 (47.04) | 17.79 |  | 7.86 |  |
Gender | Â | Â | 0.009 | Â | 0.145 |
 Male | 169 (58.89) | 13.35 |  | 7.04 |  |
 Female | 118 (41.11) | 15.65 |  | 7.36 |  |
Ethnicity | Â | Â | 0.954 | Â | 0.686 |
 Hispanic or Latino | 5 (2.21) | 14.22 |  | 5.98 |  |
 Not Hispanic or Latino | 221 (97.79) | 14.01 |  | 7.04 |  |
LANCL2 gene status | Â | Â | 0.023 | Â | 0.123 |
 Amplification | 157 (27.12) | 13.78 |  | 6.67 |  |
 No alteration | 422 (72.88) | 14.50 |  | 7.20 |  |
EGFR gene status | Â | Â | 0.042 | Â | 0.230 |
 Amplification | 252 (43.52) | 14.01 |  | 6.84 |  |
 No alteration | 327 (56.48) | 14.50 |  | 7.66 |  |
LANCL2 and EGFR genes status | Â | Â | 0.013 | Â | 0.509 |
 Co-amplification | 156 (26.94) | 13.78 |  | 6.67 |  |
 No alteration | 423 (73.06) | 14.53 |  | 7.30 |  |
LANCL2 mRNA status | Â | Â | 0.224 | Â | 0.664 |
 Overexpression | 56 (36.36) | 13.78 |  | 7.04 |  |
 No alteration | 98 (63.64) | 13.61 |  | 5.98 |  |
EGFR mRNA status | Â | Â | 0.778 | Â | 0.136 |
 Overexpression | 75 (48.70) | 14.93 |  | 6.41 |  |
 No alteration | 79 (51.30) | 12.95 |  | 6.90 |  |
LANCL2 and EGFR mRNA status | Â | Â | 0.930 | Â | 0.689 |
 Concurrent overexpression | 42 (27.27) | 15.39 |  | 6.41 |  |
 No alteration | 112 (72.73) | 13.12 |  | 6.84 |  |